Company Filing History:
Years Active: 2022
Title: The Innovations of Ivan Krivega
Introduction
Ivan Krivega is a notable inventor based in Richmond, CA. He has made significant contributions to the field of genetic engineering, particularly through his work on engineered nucleases. His innovative approach aims to enhance the specificity of these nucleases, which are crucial for targeted gene editing.
Latest Patents
Ivan Krivega holds a patent for "Engineered target specific nucleases." This patent describes engineered nucleases that include mutations in the cleavage domain, such as FokI or its homologues, and/or the DNA binding domain, which may include zinc finger proteins, TALE, or single guide RNA. The primary focus of this invention is to increase on-target specificity, which is vital for the accuracy of gene editing technologies.
Career Highlights
Ivan is currently employed at Sangamo Therapeutics, Inc., a company that specializes in genomic medicine. His work at Sangamo has positioned him at the forefront of innovative research in gene therapy and editing technologies. With a patent portfolio that includes 1 patent, he continues to contribute to advancements in the field.
Collaborations
Ivan collaborates with esteemed colleagues such as Russell DeKelver and Jeffrey C. Miller. These partnerships enhance the research and development efforts at Sangamo Therapeutics, fostering an environment of innovation and discovery.
Conclusion
Ivan Krivega's work exemplifies the intersection of innovation and practical application in genetic engineering. His contributions are paving the way for more precise and effective gene editing techniques, which hold great promise for the future of medicine.